SCHEMBL17858841

SCHEMBL17858841

CCC(=O)c1ccc(C(=O)Nc2ccc3c(c2)C(C)(C)CCC3(C)C)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP26A1 O43174 7/20 0.74
RARA P10276 6/20 0.74
RARB P10826 6/20 0.74
RARG P13631 6/20 0.74
CYP3A4 P08684 5/20 0.74
KMT2A Q03164 3/20 0.74
MEN1 O00255 2/20 0.74
PGR P06401 1/20 0.74
ADORA3 P0DMS8 1/20 0.74
TBXA2R P21731 1/20 0.74
BLVRB P30043 1/20 0.74
CYP26B1 Q9NR63 5/20 0.70
CYP1A2 P05177 2/20 0.62
ALDH1A1 P00352 1/20 0.62
CYP2C9 P11712 1/20 0.62
TSHR P16473 1/20 0.62
MAPK1 P28482 1/20 0.62
CYP2C19 P33261 1/20 0.62
MAPT P10636 1/20 0.46
RXRA P19793 5/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13027032 0.88 CYP26A1 (0.76) CYP26A1RARARARBRARGCYP3A4
SCHEMBL1615110 0.85 RARA (0.80) CYP26A1RARARARBRARGCYP3A4
SCHEMBL8461840 0.85 CYP26A1 (0.80) CYP26A1RARARARBRARGCYP3A4
Tamibarotene SCHEMBL36207 0.85 RARB (1.00) CYP26A1RARARARBRARGCYP3A4
Tamibarotene SCHEMBL29373818 0.85 RARB (1.00) CYP26A1RARARARBRARGCYP3A4
SCHEMBL19560600 0.85 RARA (0.80) CYP26A1RARARARBRARGCYP3A4
SCHEMBL13999715 0.85 CYP26A1 (0.80) CYP26A1RARARARBRARGCYP3A4
SCHEMBL2896779 0.84 CYP26A1 (0.77) CYP26A1RARARARBRARGCYP3A4
Tamibarotene SCHEMBL21055743 0.84 RARB (0.97) CYP26A1RARARARBRARGCYP3A4
SCHEMBL8461304 0.84 RARA (0.78) CYP26A1RARARARBRARGCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9452220-B2 Coupling compounds of NSAID anti-inflammatory and analgesic drugs and EGFR kinase inhibitors, synthesis methods and applications thereof GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) 2016-09-27 US disclosed
US-20160175453-A1 COUPLING COMPOUNDS OF NSAID ANTI-INFLAMMATORY AND ANALGESIC DRUGS AND EGFR KINASE INHIBITORS, SYNTHESIS METHODS AND APPLICATIONS THEREOF GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) 2016-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160175453-A1 COUPLING COMPOUNDS OF NSAID ANTI-INFLAMMATORY AND ANALGESIC DRUGS AND EGFR KINASE INHIBITORS, SYNTHESIS METHODS AND APPLICATIONS THEREOF EGFR, CHUK, ERBB2 CYP26A1 695/4885RARA 2171/4885RARB 1926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.